Treatment
Your treatment plan is based not only on the cancer’s triple-negative status but also the cancer stage and other factors included in your pathology report after a biopsy or other breast cancer-removing surgery. These factors may include:
- The tumor size
- The cancer’s grade, which shows how quickly the cancer cells are dividing and how different they look from normal cells
- Whether the cancer has traveled to lymph nodes
If the cancer is metastatic, your doctor may also recommend testing for a protein called PD-L1. PD-L1-positive triple-negative breast cancer is eligible for immunotherapy treatment.
Treating early-stage triple-negative breast cancer
Treatment for early-stage triple-negative breast cancer depends on whether the cancer is small enough to be removed with surgery, or if chemotherapy is needed first to shrink a larger tumor and/or any cancer in the lymph nodes.
Treating smaller triple-negative breast cancers
Treatment options can include:
Treating larger triple-negative breast cancers
For larger cancers that have a higher risk of coming back (recurrence), treatments may be given first to shrink the tumor and any cancer in the lymph nodes. This is called neoadjuvant therapy. These treatments may include:
After surgery, more treatments may be given to destroy any remaining cancer cells and lower the risk of recurrence. These can include:
Your doctor can help you decide what combination of treatments makes sense for your situation and the features of the cancer.
Treating metastatic triple-negative breast cancer
For metastatic triple-negative breast cancer, first treatment options are based on:
Treatment plans may include the following medicines:
Immunotherapy
Immunotherapy helps the body’s immune system slow or stop cancer growth. Pembrolizumab is an immunotherapy approved to treat metastatic triple-negative breast cancer that tests positive for the PD-L1 protein.
Antibody-drug conjugates
Antibody-drug conjugates are medicines that pair a targeted therapy with chemotherapy to deliver chemotherapy directly to cancer cells. Three antibody-drug conjugates are available to treat metastatic triple-negative metastatic breast cancer:
PARP inhibitors
PARP inhibitors are targeted therapies that stop an enzyme called PARP from repairing cancer cell DNA. In order to receive these medicines, you must also test positive for an inherited BRCA mutation. There are two PARP inhibitors approved to treat metastatic TNBC:
Common first treatments and combinations
If the cancer tests positive for the PD-L1 protein, first treatments may include:
If the cancer tests negative for PD-L1, first treatment may include sacituzumab govitecan alone or datopotamab deruxtecan.
If the cancer tests negative for PD-L1 negative but the person has an inherited BRCA mutation, first treatment may include:
Your care team may also discuss clinical trials with you. Clinical trials are research studies that can provide access to treatments that may be more effective than currently approved medicines.
Radiation therapy
Radiation therapy may be used to treat any areas of cancer spread that are causing pain, discomfort, or other symptoms. These may affect the bones, brain, spine, or chest area.
Surgery
Surgery is not usually part of treatment for metastatic breast cancer, but it may be done in certain circumstances, such as removing a tumor that is causing pain, or helping to stabilize bones affected by bone metastasis.
More about triple-negative MBC and treatment
Visit these pages to learn more about triple-negative metastatic breast cancer and treatment options: